Get the Stockscreener App
61.10
5.07%
-3.26
Pre-market:
60.85
-0.25
-0.41%
Disc Medicine Inc stock is traded at $61.10, with a volume of 643.08K.
It is down -5.07% in the last 24 hours and down -25.17% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$64.36
Open:
$65.03
24h Volume:
643.08K
Relative Volume:
0.92
Market Cap:
$2.31B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-16.65
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-8.66%
1M Performance:
-25.17%
6M Performance:
+1.51%
1Y Performance:
+10.41%
1-Day Range:
$60.92
$65.03
1-Week Range:
$60.92
$68.19
52-Week Range:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
61.10 | 2.43B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock - MarketBeat
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst - AOL.com
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection - AOL.com
IRON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IRON: Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024 - TradingView
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - MarketBeat
Disc Medicine, Inc. (IRON) Stock Analysis: A 50% Potential Upside In The Biotech Sector - DirectorsTalk Interviews
IRON (NASDAQ: IRON) proposed insider sales including 13,093-share 12/15/2025 sale - Stock Titan
Watertown biotech cuts 20% of staff after FDA rejects rare disease drug - The Business Journals
IRON: Wells Fargo Raises Price Target for Disc Medicine | IRON S - GuruFocus
Disc Medicine (NASDAQ:IRON) Price Target Raised to $79.00 - MarketBeat
Disc Medicine Refocuses On APOLLO Trial After FDA Letter For Bitopertin - Sahm
Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf RegistrationWhat's Changed - Yahoo Finance
A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings - Sahm
Disc Medicine (IRON) Announces Restructuring Following FDA Setba - GuruFocus
Disc Medicine announces workforce reduction and restructuring plan By Investing.com - Investing.com Australia
Disc Medicine announces workforce reduction and restructuring plan - Investing.com Nigeria
Insider Sell: Jean Franchi Sells Shares of Disc Medicine Inc (IR - GuruFocus
Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock - MarketBeat
Disc Medicine Implements Restructuring Following FDA Response - TipRanks
Disc Medicine's board approves restructuring plan - marketscreener.com
Disc Medicine (IRON) CFO sells 353 shares under 10b5-1 plan - Stock Titan
Disc Medicine (IRON) trims workforce 20% after FDA letter, books $2M charge - Stock Titan
Disc Medicine (NASDAQ:IRON) Price Target Lowered to $83.00 at Truist Financial - MarketBeat
JPMorgan Chase & Co. Sells 90,737 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results - MarketBeat
Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Disc Medicine's 2025 Net Loss Widens - marketscreener.com
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-K Report - TradingView
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Disc Medicine's 2025 net loss smaller than estimates - TradingView
Disc Medicine (NASDAQ: IRON) faces FDA CRL as hematology pipeline advances - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2025 loss, cash runway and FDA letter - Stock Titan
After FDA setback, Disc Medicine pushes rare blood drugs with $791M cash - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - AOL.com
Jean Franchi sells 7,081 IRON shares under 10b5-1 (IRON) - Stock Titan
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction - The Motley Fool
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients - TipRanks
Opinion | Who’s in Charge at the FDA? - WSJ
IRON SEC FilingsDisc Medicine Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Shorts: Should I invest in Disc Medicine Inc before earningsPortfolio Value Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Disc Medicine, Inc. (IRON) Stock Analysis: A High-Risk, High-Reward Play with 61.59% Potential Upside - DirectorsTalk Interviews
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Disc Medicine lines up four investor events in March - Stock Titan
Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4 - MarketBeat
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route - AOL.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):